Copyright Reports & Markets. All rights reserved.

Global Immuno-Oncology Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Immuno-Oncology Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Immune Checkpoint Inhibitors
      • 1.4.3 Monoclonal Antibodies
      • 1.4.4 Cytokine-Based Immunotherapy
      • 1.4.5 Cancer Vaccines
      • 1.4.6 CAR-T Cell Therapy
    • 1.5 Market by Application
      • 1.5.1 Global Immuno-Oncology Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Pharmacies
      • 1.5.4 Online Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Immuno-Oncology Market Size
    • 2.2 Immuno-Oncology Growth Trends by Regions
      • 2.2.1 Immuno-Oncology Market Size by Regions (2014-2025)
      • 2.2.2 Immuno-Oncology Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Immuno-Oncology Market Size by Manufacturers
      • 3.1.1 Global Immuno-Oncology Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Immuno-Oncology Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Immuno-Oncology Market Concentration Ratio (CR5 and HHI)
    • 3.2 Immuno-Oncology Key Players Head office and Area Served
    • 3.3 Key Players Immuno-Oncology Product/Solution/Service
    • 3.4 Date of Enter into Immuno-Oncology Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Immuno-Oncology Market Size by Type (2014-2019)
    • 4.2 Global Immuno-Oncology Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Immuno-Oncology Market Size (2014-2019)
    • 5.2 Immuno-Oncology Key Players in United States
    • 5.3 United States Immuno-Oncology Market Size by Type
    • 5.4 United States Immuno-Oncology Market Size by Application

    6 Europe

    • 6.1 Europe Immuno-Oncology Market Size (2014-2019)
    • 6.2 Immuno-Oncology Key Players in Europe
    • 6.3 Europe Immuno-Oncology Market Size by Type
    • 6.4 Europe Immuno-Oncology Market Size by Application

    7 China

    • 7.1 China Immuno-Oncology Market Size (2014-2019)
    • 7.2 Immuno-Oncology Key Players in China
    • 7.3 China Immuno-Oncology Market Size by Type
    • 7.4 China Immuno-Oncology Market Size by Application

    8 Japan

    • 8.1 Japan Immuno-Oncology Market Size (2014-2019)
    • 8.2 Immuno-Oncology Key Players in Japan
    • 8.3 Japan Immuno-Oncology Market Size by Type
    • 8.4 Japan Immuno-Oncology Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Immuno-Oncology Market Size (2014-2019)
    • 9.2 Immuno-Oncology Key Players in Southeast Asia
    • 9.3 Southeast Asia Immuno-Oncology Market Size by Type
    • 9.4 Southeast Asia Immuno-Oncology Market Size by Application

    10 India

    • 10.1 India Immuno-Oncology Market Size (2014-2019)
    • 10.2 Immuno-Oncology Key Players in India
    • 10.3 India Immuno-Oncology Market Size by Type
    • 10.4 India Immuno-Oncology Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Immuno-Oncology Market Size (2014-2019)
    • 11.2 Immuno-Oncology Key Players in Central & South America
    • 11.3 Central & South America Immuno-Oncology Market Size by Type
    • 11.4 Central & South America Immuno-Oncology Market Size by Application

    12 International Players Profiles

    • 12.1 Amgen, Inc
      • 12.1.1 Amgen, Inc Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Immuno-Oncology Introduction
      • 12.1.4 Amgen, Inc Revenue in Immuno-Oncology Business (2014-2019)
      • 12.1.5 Amgen, Inc Recent Development
    • 12.2 AstraZeneca, Plc
      • 12.2.1 AstraZeneca, Plc Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Immuno-Oncology Introduction
      • 12.2.4 AstraZeneca, Plc Revenue in Immuno-Oncology Business (2014-2019)
      • 12.2.5 AstraZeneca, Plc Recent Development
    • 12.3 Bristol-Myers Squibb
      • 12.3.1 Bristol-Myers Squibb Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Immuno-Oncology Introduction
      • 12.3.4 Bristol-Myers Squibb Revenue in Immuno-Oncology Business (2014-2019)
      • 12.3.5 Bristol-Myers Squibb Recent Development
    • 12.4 Celgene Corporation
      • 12.4.1 Celgene Corporation Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Immuno-Oncology Introduction
      • 12.4.4 Celgene Corporation Revenue in Immuno-Oncology Business (2014-2019)
      • 12.4.5 Celgene Corporation Recent Development
    • 12.5 Eli Lilly and Company
      • 12.5.1 Eli Lilly and Company Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Immuno-Oncology Introduction
      • 12.5.4 Eli Lilly and Company Revenue in Immuno-Oncology Business (2014-2019)
      • 12.5.5 Eli Lilly and Company Recent Development
    • 12.6 Merck & Co.
      • 12.6.1 Merck & Co. Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Immuno-Oncology Introduction
      • 12.6.4 Merck & Co. Revenue in Immuno-Oncology Business (2014-2019)
      • 12.6.5 Merck & Co. Recent Development
    • 12.7 Hoffmann-La Roche AG
      • 12.7.1 Hoffmann-La Roche AG Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Immuno-Oncology Introduction
      • 12.7.4 Hoffmann-La Roche AG Revenue in Immuno-Oncology Business (2014-2019)
      • 12.7.5 Hoffmann-La Roche AG Recent Development
    • 12.8 Johnson & Johnson
      • 12.8.1 Johnson & Johnson Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Immuno-Oncology Introduction
      • 12.8.4 Johnson & Johnson Revenue in Immuno-Oncology Business (2014-2019)
      • 12.8.5 Johnson & Johnson Recent Development
    • 12.9 Novartis International AG
      • 12.9.1 Novartis International AG Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Immuno-Oncology Introduction
      • 12.9.4 Novartis International AG Revenue in Immuno-Oncology Business (2014-2019)
      • 12.9.5 Novartis International AG Recent Development
    • 12.10 AbbVie
      • 12.10.1 AbbVie Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Immuno-Oncology Introduction
      • 12.10.4 AbbVie Revenue in Immuno-Oncology Business (2014-2019)
      • 12.10.5 AbbVie Recent Development
    • 12.11 Pfizer Inc.
    • 12.12 Sanofi S.A.
    • 12.13 EMD Serono
    • 12.14 Gilead Sciences Inc.
    • 12.15 Prometheus Therapeutics & Diagnostics
    • 12.16 Aduro BioTech
    • 12.17 Galena Biopharma
    • 12.18 Bavarian Nordic
    • 12.19 Celldex Therapeutics
    • 12.20 ImmunoCellular Therapeutics
    • 12.21 Incyte

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
      In 2018, the global Immuno-Oncology market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Immuno-Oncology status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immuno-Oncology development in United States, Europe and China.

      The key players covered in this study
      Amgen, Inc
      AstraZeneca, Plc
      Bristol-Myers Squibb
      Celgene Corporation
      Eli Lilly and Company
      Merck & Co.
      Hoffmann-La Roche AG
      Johnson & Johnson
      Novartis International AG
      AbbVie
      Pfizer Inc.
      Sanofi S.A.
      EMD Serono
      Gilead Sciences Inc.
      Prometheus Therapeutics & Diagnostics
      Aduro BioTech
      Galena Biopharma
      Bavarian Nordic
      Celldex Therapeutics
      ImmunoCellular Therapeutics
      Incyte

      Market segment by Type, the product can be split into
      Immune Checkpoint Inhibitors
      Monoclonal Antibodies
      Cytokine-Based Immunotherapy
      Cancer Vaccines
      CAR-T Cell Therapy

      Market segment by Application, split into
      Hospitals
      Pharmacies
      Online Pharmacies

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Immuno-Oncology status, future forecast, growth opportunity, key market and key players.
      To present the Immuno-Oncology development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Immuno-Oncology are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now